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ABSTRACT
Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible
to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant
opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive
revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of
these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg
and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing
bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been
isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial
susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial
resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections.
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SEARCH STRATEGY AND SELECTION
CRITERIA
Data for this review were obtained through
searches of Medline and Pubmed, from references
cited in relevant articles, through searches of
abstracts and posters presented at different na-
tional and international meetings, from the world-
wide web, and from surveillance studies,
associated with the introduction of new agents,
conducted by the pharmaceutical industry. Search
terms used were ‘Acinetobacter’, ‘antimicrobial
resistance’, ‘antibiotics’, ‘carbapenems’, ‘amino-
glycosides’, ‘quinolones’ and ‘treatment’. Only
studies published in English, French, German or
Dutch were reviewed. The first phase of the
literature search resulted in the identification of
> 3500 references, but initial review of the
abstracts revealed that many articles were dupli-
cated across the different search strategies. After
exclusion of duplicate references, 2158 studies
published between 1963 and 2003 remained. Of
these, 267 were downloaded for detailed review.
THE ACINETOBACTER GENUS AND
CLINICALLY IMPORTANT SPECIES
Acinetobacter spp. are glucose-non-fermentative,
non-fastidious, strictly aerobic Gram-negative
coccobacilli, usually occurring in diploid forma-
tion, or in chains of variable length. They are non-
motile, catalase-positive and oxidase-negative [1].
Since 1986, the taxonomy of the genus Acinetob-
acter has undergone extensive revision. The ori-
ginal single species named Acinetobacter
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calcoaceticus has been abandoned, and at least 32
genomic species have now been proposed, of
which 17 have been assigned species names.
Correct identification of acinetobacters to the
species level by the use of phenotypic methods
is problematic [2,3]. In particular, discrimination
between Acinetobacter baumannii and the genetic-
ally closely related unnamed genomic species 3
and 13 sensu Tjernberg and Ursing (13TU) is
difficult. Genotypic methods, such as amplified
ribosomal DNA restriction analysis [4] and ana-
lysis of whole genome fingerprints obtained by
selective amplification of restriction fragments
[5,6], have been useful for precise species identi-
fication when tested against libraries of well-
validated strains, but these methods are not
currently suitable for use in routine clinical
diagnostic microbiology laboratories.
Studies using well-validated identification
methods have shown clearly that most clinical
isolates are strains of A. baumannii [7], and that
this species, and to a lesser extent the closely
related unnamed genomic species 3 and 13TU, are
responsible for most infections and hospital out-
breaks involving Acinetobacter spp. [3,4,6,8–11].
Other species, such as Acinetobacter junii, have
been implicated only occasionally in outbreaks of
nosocomial infection [3].
It is worth emphasising that the species names
mentioned in the present review are those used
by the authors of the original papers, and should
be considered with some caution, given the
problems of phenotypic identification in most of
the studies reviewed. In articles published before
the mid-1980s, the taxonomic status of the organ-
isms is even more obscure, since, at that time,
the genus Acinetobacter included only one all-
encompassing species. Because of these consider-
ations, acinetobacters are denoted as Acinetobacter
spp. in the current review if their taxonomic
status at the species level is uncertain.
NOSOCOMIAL INFECTIONS CAUSED
BY ACINETOBACTER SPP .
Acinetobacter spp. are recognised as important
opportunistic pathogens mainly in immunocom-
promised patients [12]. Their contribution to
nosocomial infection has increased over the past
three decades, and many outbreaks of hospital
infection involving acinetobacters have been
reported worldwide. According to data from the
National Nosocomial Infections Surveillance sys-
tem, Acinetobacter spp. were isolated in 1% of all
nosocomial infections from 1990 to 1992 [13].
However, the true frequency of nosocomial infec-
tion caused by Acinetobacter spp. is difficult to
assess because isolation of Acinetobacter spp. in
clinical specimens may reflect colonisation rather
than infection [14].
Although prevalent in nature and regarded
generally as commensals of human skin and the
human respiratory tract, acinetobacters have also
been implicated as the cause of serious infectious
diseases such as pneumonia, urinary tract infec-
tion, endocarditis, wound infection, meningitis
and septicaemia, involving mostly patients with
impaired host defences [12]. Acinetobacter spp.
have emerged as particularly important organ-
isms in intensive care units (ICUs), and this is
probably related, at least in part, to the increas-
ingly invasive diagnostic and therapeutic proce-
dures used in hospital ICUs in recent years [12].
Risk factors for acquisition of Acinetobacter spp.
include hospitalisation, poor general medical
status of patients, mechanical ventilation, cardio-
vascular or respiratory failure, previous infection
or antimicrobial therapy, and the presence of
central venous or urinary catheters [15].
EPIDEMIOLOGY OF ACINETOBACTER
SPP .
Acinetobacters are ubiquitous in nature; they can
be recovered easily from soil or water, and have
also been found frequently in animal and human
hosts [16]. Several studies during the 1960s and
1970s reported isolation of these organisms
from the skin of healthy individuals at rates of
0.8–20% for glucose-acidifying acinetobacters
(Herellea vaginicola c.q. Acinetobacter anitratus), and
0–33.6% for glucose-non-acidifying acinetobacters
(Mima polymorpha c.q. Acinetobacter lwoffii) [17–20].
Skin colonisation of patients plays an important
role in the subsequent contamination of the hands
of hospital staff during contacts, thereby contribu-
ting to the spread of the organisms [21]. High
colonisation rates of the skin, throat, respiratory
system or digestive tract, of various degrees of
importance, have been documented in several
outbreaks. However, general conclusions on the
clinical significance of skin and mucosal Acinetob-
acter carriage are difficult to draw if the organisms
are not identified correctly to the species level.
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The epidemiology of Acinetobacter at the local
institutional level can be investigated without
reference to the taxonomy if the organisms are
typed using appropriate methods. Cell-envelope
protein profiling has shown that multiple body
sites of patients can be colonised with clinically
relevant strains for days to weeks, even if the
organisms were not detected in clinical specimens
of patients [22,23]. Two recent studies in Germany
and the UK, using accurate identification meth-
ods, have reported carriage of acinetobacters on
the body surface in patients and ⁄ or healthy
individuals [24,25]. Overall colonisation rates for
Acinetobacter spp. were > 40% for volunteers, and
75% for patients, when multiple body sites were
sampled. Interestingly, A. baumannii and the
unnamed genomic species 13TU, which predom-
inate in hospital infections, were rarely isolated in
the German study, while the unnamed genomic
species 3 represented 11% of the total number of
isolates, but was not detected in the UK study. In
a similar study in Hong Kong [26], A. baumannii
and spp. 3 and 13TU had a relatively high
prevalence, both in patients and in healthy indi-
viduals, with a surprising level of > 35% for sp. 3
in community individuals and student nurses.
The reservoirs from which epidemic strains are
imported into hospitals have not yet been eluci-
dated. A recent study in New York, which
compared A. baumannii strains from patients in
two hospitals with isolates from the hands of
community members, showed that strains in
the community were distinct from those in the
hospitals [27]. The authors concluded that the
reservoir for epidemic strains was in the hospital
itself.
CLONAL SPREAD OF EPIDEMIC
STRAINS
A study comparing outbreak and non-outbreak
A. baumannii isolates allowed delineation of two
groups of genetically highly related, multiresist-
ant strains among outbreak isolates from differ-
ent northwestern European cities [4]. It was
hypothesised that these groups represented two
clonal lineages, the occurrence of which has
since been reported also in the Czech Republic
[10]. A third clone of widespread multiresistant
strains from hospitals in other European coun-
tries was described by van Dessel et al. [28].
Most recently, the spread of another A. baumannii
clone among 24 hospitals in the London (UK)
region has been detected (J. Turton et al., unpub-
lished results). The possible relatedness of the
above clones to an amikacin-resistant strain that
has spread among eight hospitals in Spain has
not yet been investigated [29]. Overall, the
findings from these studies indicate that several
clones are responsible for many outbreaks in
Europe.
THE EMERGENCE OF RESISTANCE
Acinetobacter spp. have become resistant to almost
all antimicrobial agents that are currently avail-
able, including the aminoglycosides, quinolones
and broad-spectrum b-lactams. Most strains are
resistant to cephalosporins, while resistance to
carbapenems is being reported increasingly
[30,31]. Important differences in antimicrobial
susceptibility exist between A. baumannii and
other species in the genus, with A. baumannii
being the most resistant species [32–34]. Difficulty
in eradicating these bacteria has allowed them to
colonise niches left vacant following the eradica-
tion of more susceptible microbes.
This review provides an overview of the
evolution of the susceptibilities of Acinetobacter
spp. to the different antimicrobial classes. How-
ever, it should be stressed that comparison of
susceptibility rates between studies is rendered
difficult, not only because of variations in local
epidemiology, antibiotic selection pressure and
patient populations, but also because of differ-
ences in study protocols. Thirty-one studies
concerning the antimicrobial surveillance of
Acinetobacter spp. in Europe were identified. An
overview of these studies is given in Table 1.
Duplicates were excluded and internal quality
control through the use of standard control
strains was performed in most of the studies.
One study used the breakpoints recommended
by the British Society for Antimicrobial Chemo-
therapy (BSAC), another did not specify the
breakpoints used, and the remaining studies
used the breakpoints recommended by the
National Committee for Clinical Laboratory
Standards. The identification methods used for
the Acinetobacter strains were heterogeneous;
however, as mentioned above, species identifica-
tion using a correct method is an important factor
to be taken into account when comparing differ-
ent studies.
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b-Lactams
Acinetobacter is resistant to most b-lactam antibi-
otics, particularly penicillins and cephalosporins,
especially in ICU patients [32–35]. Ceftazidime,
piperacillin and carbapenems are among the
b-lactam antibiotics most active against A. bau-
mannii.
The main mechanism of resistance to b-lactam
antibiotics in Acinetobacter spp. is the production
of b-lactamases encoded either by the chromo-
some or by plasmids [36]. In addition, the low
permeability of the outer-membrane of Acinetob-
acter, resulting from the small outer-membrane
pore size and ⁄ or limited porin production [37], as
well as alterations in the affinity of penicillin-
binding proteins (PBPs), have been implicated in
the resistance of Acinetobacter to these antibiotics.
Danes et al. [38] described the distribution of
b-lactamases in a collection of epidemiologically
unrelated A. baumannii clinical isolates. The
results suggested that over-expression of the
chromosomal cephalosporinase AmpC could play
an important role in resistance to b-lactam anti-
biotics.
Resistance to ampicillin, carboxypenicillin and
ureidopenicillin has been attributed to the pro-
duction of TEM-1 [34,39], TEM-2 [40], OXA-21
[38,41] or OXA-37 [42] b-lactamase. Most of the
TEM and SHV types of extended-spectrum
b-lactamases have not yet been detected in
A. baumannii. The non-TEM, non-SHV extended-
spectrum b-lactamases PER-1 and VEB-1 are the
only extended-spectrum b-lactamases reported to
date in A. baumannii. PER-1 has been detected in
Turkish and French isolates [43–45]. An epidemi-
ological survey performed in Turkey in 1996
identified the spread of PER-1-positive A. bau-
mannii isolates [44], and infections with these
isolates positive for PER-1 have been associated
with a higher risk of mortality [45]. Isolates of A.
baumannii producing VEB-1 were associated with
a French outbreak in 2001 [46].
Carbapenems have become the preferred treat-
ment for serious Acinetobacter infections in many
centres, and have retained better activity than
other antimicrobial agents; however, the number
of reports of carbapenem resistance is growing
steadily and is a cause for concern. In the last few
years, carbapenem-resistant Acinetobacter isolates
have been reported worldwide [47,48]. In nor-
thern Europe, carbapenem-resistant strains of
A. baumannii have been mostly sporadic, but in
some southern European countries, including
parts of Spain, they are endemic [49,50]. In 2001,
the International Network for the Study and
Prevention of Emerging Antimicrobial Resistance
(INSPEAR) defined the emergence of carbapenem
resistance in Acinetobacter as a ‘global sentinel
event’, warranting prompt epidemiological and
microbiological interventions [51].
Several mechanisms of carbapenem resistance
have been described in A. baumannii, including
loss of outer-membrane proteins [52] and altered
PBPs [53]. In addition, isolates of A. baumannii
can acquire carbapenemases, including class B
metallo-b-lactamases [54,55] and class A and D
b-lactamases [56–59]. A combination of several
mechanisms may be present in the same isolate,
as has been described in other Gram-negative
bacteria [49]. In general, the prevalence of carba-
penemases is still relatively limited compared to
the prevalence of other b-lactamases [60].
The first known A. baumannii isolate with a
carbapenem-hydrolysing b-lactamase was collec-
ted in 1985 in Scotland, and was initially desig-
nated ARI-1 (subsequently renamed OXA-23)
[30]. This enzyme hydrolyses imipenem and also
confers resistance to penicillins, but not to second-
and third-generation cephalosporins. A later
study of this isolate identified a plasmid location
for the OXA-23 gene [61]. Acinetobacter isolates
producing carbapenemases have now been repor-
ted from at least 12 countries, including Belgium,
France, Italy, Spain and the UK [56]. Some of
these carbapenemases are IMP- or VIM-type met-
allo-b-lactamases belonging to class B [55,62,63],
but most carbapenem-resistant acinetobacters
produce zinc-independent b-lactamases of class
D [56]. Sequenced carbapenemases from acine-
tobacters of this latter class include OXA-23
(ARI-1) [59], OXA-24 [57], OXA-25, OXA-26,
OXA-27 [56] and OXA-40 [64]. The OXA-type
b-lactamases all have relatively weak activity
against carbapenems.
In a study from Germany in the early 1990s,
imipenem was found to be the most active agent
against A. baumannii. All 180 Acinetobacter spp.
isolates tested were fully susceptible to imipenem.
Amoxycillin–clavulanate showed moderate activ-
ity, whereas ampicillin, broad-spectrum penicillins
and cephalosporins were less active. Similarly, in
another report dating from 1991, 23 Acinetobacter
spp. isolates were obtained from ICU patients in
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ten German hospitals. Ceftazidime and imipenem
were the most active b-lactam antibiotics, with 96%
of the isolates remaining susceptible. Susceptibili-
ties to piperacillin and cefotaxime were 65% and
61%, respectively [65]. All 11 Acinetobacter spp.
strains isolated in 1990 from patients in eight Dutch
hospitals were susceptible to imipenem, and ten
(91%) of the strains were susceptible to ceftazi-
dime, ceftriaxone and amoxycillin–clavulanate
[66].
Acinetobacter spp. collected between June 1994
and June 1995 from ICUs in five European
countries showed susceptibilities to ceftazidime
of 82% in Belgium, 30% in France, 19% in
Portugal, 24% in Spain and 100% in Sweden.
Susceptibilities to imipenem were 88% in Bel-
gium, 91% in France, 95% in Portugal, 84% in
Spain and 81% in Sweden [67,68]. In 1990, 70
Acinetobacter spp. from ICU patients in 16 Belgian
hospitals showed susceptibilities to imipenem,
ceftazidime and ceftriaxone of 93%, 86% and
74%, respectively [69].
Between September and October 1992, 111
Acinetobacter spp. were collected in 28 Belgian
hospitals. Ceftazidime was the most active agent
(78% susceptible), followed by cefepime (74%),
cefotaxime (66%), piperacillin (56%) and aztreo-
nam (47%) [70]. During 1996–1997 and 1998–1999,
41 and 11 Acinetobacter spp., respectively, were
collected in the ICUs of Belgian hospitals. Imipe-
nem (90% and 89%) and ceftazidime (80% and
100%) were the most active agents. Some import-
ant changes in resistance rates took place between
both collections. However, the small number of
isolates, as well as the lack of complete identifi-
cation to the species level for most isolates,
precluded any comparison between both collec-
tion periods [71].
In the UK, 13 (2.2%) of 595 Acinetobacter spp.
isolated during 2000 from routine clinical speci-
mens at 54 sentinel laboratories were carbape-
nem-resistant (BSAC breakpoint, MIC ‡ 8 mg ⁄L)
[72]. An allele of blaIMP was detected in one of
these isolates, but the other 12 isolates either had
carbapenemase-independent resistance, or unde-
tectable carbapenemase activity combined with
other resistance mechanisms. Routine surveil-
lance data obtained in 2001 from England and
Wales similarly showed only 1% resistance to
imipenem in bacteraemia isolates of Acinetobacter
spp. [73]. These results are in sharp contrast
to those of the MYSTIC (Meropenem Yearly
Susceptibility Test Information Collection) study
reported below [74]; however, only isolates of
A. baumannii were investigated in the MYSTIC
study.
Of 268 A. baumannii isolates from French
teaching hospitals in 1991, 21% were susceptible
to piperacillin and cefotaxime, 20% to aztreonam,
71% to ceftazidime, and 100% to imipenem [75].
Similar results were reported with 177
A. calcoaceticus–A. baumannii complex strains iso-
lated in 1990–1994 from patients admitted to a
Spanish teaching hospital. Imipenem and me-
ropenem (99% susceptibility) were the most
active agents tested, with 97% of isolates being
susceptible to ampicillin–sulbactam. Only 25% of
the isolates were susceptible to ceftazidime [76].
In a Spanish study published in 1993, almost all
54 A. baumannii isolates tested were resistant to
both ampicillin and amoxycillin. Addition of the
b-lactamase inhibitor sulbactam increased the
percentage of strains susceptible to ampicillin to
52%, while the addition of clavulanic acid to
amoxycillin or ticarcillin did not significantly
change the percentage of susceptible strains.
However, the enhanced activity in the presence
of sulbactam may be attributable to the activity of
sulbactam alone. More than 50% of the isolates
were resistant to piperacillin, cefotaxime, ticarcil-
lin and ceftazidime [34].
Other Spanish studies have also documented
significant levels of resistance. In one study,
ceftazidime resistance increased from 57.4% in
1991 to 86.8% in 1996, while imipenem resistance
increased from 1.3% to 80.0% [77]. In another
study, seven (21%) of 34 multiresistant clinical
isolates recovered during 1990–1995 were resist-
ant to imipenem [78]. In a third study during the
period 1997–1999, isolates from patients with
nosocomial A. baumannii bacteraemia were stud-
ied. Of 109 isolates, 71% were resistant to cefotax-
ime, 66% to ceftazidime, and 34% to imipenem
[79]. In a fourth study, of 64 A. baumannii isolates
obtained from 12 Spanish medical centres in 2001,
37.5% were resistant to cefepime, and 28.1% to
imipenem [80]. Finally, in a hospital in Seville, all
A. baumannii isolates in blood were susceptible to
imipenem in 1991, whereas 50% were resistant to
imipenem in 2000 [81].
In Greece, all A. baumannii isolates in the Greek
WHONET study in 1996 were fully susceptible to
imipenem (http://mednet.gr/whonet) [82]. Dur-
ing a 4-month period from January to April 1998,
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121 clinical isolates of A. baumannii were collected
from patients hospitalised in the ICUs of nine
Greek tertiary care hospitals. High rates of resist-
ance to b-lactam antibiotics, such as aztreonam
(93.4%) and ceftazidime (95.9%), were detected,
but imipenem-resistant acinetobacters were not
isolated. However, after the study period, a few
imipenem-resistant acinetobacters emerged in a
large Greek hospital that had participated in the
study [83].
In Turkey, a surveillance study in 1996 of
Gram-negative bacteria isolated from ICUs in
eight hospitals found that 5% of 80 Acinetobacter
spp. isolates were susceptible to cefotaxime and
ceftriaxone, 7.5% to ceftazidime, 11.2% to cefep-
ime, and 71.2% to imipenem [84]. When the study
was repeated in 1997, no antibacterial agent other
than imipenem was effective against Acinetobacter
spp., and of the 164 isolates investigated, only
49.3% were susceptible to imipenem [85]. Also in
Turkey, a multicentre evaluation in 1997 of seven
broad-spectrum b-lactams found that the 80
Acinetobacter spp. isolates investigated were gen-
erally not susceptible to ceftazidime, cefotaxime,
aztreonam or ticarcillin–clavulanate (range 17.2–
29.3% susceptible), but were more susceptible to
both imipenem (85.0%) and cefoperazone–sul-
bactam (73.8%) [86], although the latter finding
could be caused by the intrinsic activity of
sulbactam against Acinetobacter spp.
A third Turkish study in 1999 of 32 A. baumannii
isolates from the ICUs of four different hospitals
found that 5.6% were susceptible to cefotaxime,
3.1% to ceftriaxone, 20.6% to ceftazidime, and
100% to imipenem [87].
In Croatia, imipenem resistance rates of Acine-
tobacter spp. in 1999 varied between 0% and 8%
in 22 Croatian microbiology laboratories repre-
senting the major geographical regions of the
country, with 18% of isolates resistant to ampi-
cillin–sulbactam [88]. In a Slovakian study
published in 2002, 46 (92%) of 50 clinical Acine-
tobacter spp. isolates (A. baumannii, A. lwoffii,
A. calcoaceticus, A. haemolyticus) were resistant to
ampicillin, 90% to cefuroxime, 58% to piperacil-
lin, 50% to cefotaxime, 42% to ceftazidime, 38%
to piperacillin–tazobactam, and 16% to ampicil-
lin–sulbactam. None of the isolates was resistant
to meropenem [89].
In Poland, all 32 isolates investigated during
1997–2000 remained susceptible to imipenem and
meropenem (MIC90 0.5-2 mg ⁄L) [90], while a 1995
study in the ICUs of an Estonian university
hospital found that 56% of Acinetobacter spp.
isolates were susceptible to ceftazidime, decreas-
ing to 43% in 1998. In 1998, 47% of isolates
remained susceptible to cefepime, with a small
increase in susceptibility to imipenem from 93%
in 1995 to 99% in 1998 [91]. In ten Russian
hospitals between September 1995 and May 1996,
77 Acinetobacter spp. strains isolated from ICU
patients showed high resistance rates to b-lactam
antibiotics, ranging between 73% and 96%. Imi-
penem was the most active agent, with all isolates
remaining susceptible [92].
In the 1997–1998 European arm of the SENTRY
antimicrobial surveillance programme, imipenem
and meropenem were the most active drugs
against Acinetobacter spp. isolated from blood,
with 80.2% and 78.1%, respectively, of the 247
Acinetobacter spp. isolates remaining susceptible.
Of the cephalosporins tested, ceftazidime and
cefepime were the most active, although only
51.4% and 62.8%, respectively, of the isolates
remained susceptible to these agents [93]. In 1997,
the antimicrobial susceptibilities of 41 Acinetob-
acter spp. isolates associated with skin and soft
tissue infections were determined in the SENTRY
study. Imipenem was the most active b-lactam
compound tested, with 90.2% of the isolates being
susceptible. Susceptibilities to meropenem, ceft-
azidime and cefepime were 85.4%, 41.5% and
48.8%, respectively [94].
Among the 490 A. baumannii isolates from
patients with serious infections in 37 European
hospitals participating in the 1997–2000 MYSTIC
programme, the two carbapenems showed the
greatest clinically useful activity. Susceptibilities
of A. baumannii to meropenem were very high
(97–100%) in all countries except Italy (70%),
Turkey (66%) and the UK (77%). A similar
pattern was seen for imipenem (93–100%), except
for Italy (78%), Turkey (62%) and the UK (78%).
The 51 isolates of A. calcoaceticus var. lwoffii were
more susceptible than A. baumannii. Susceptibilit-
ies of A. calcoaceticus var. lwoffii to meropenem
and imipenem were 100% in all countries except
Turkey, where there was 87% susceptibility to
meropenem, and 73% susceptibility to imipenem.
For the 94 isolates of other Acinetobacter spp., high
(91–100%) susceptibilities to meropenem and
imipenem were seen in all countries that obtained
isolates from this group, except Italy (88%) and
Turkey (27%) [74].
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Data from the 1999–2000 ESAR (European
Surveillance of Antibiotic Resistance) study
showed no resistance of Acinetobacter to carbap-
enems in Scotland (0 ⁄ 1316 isolates), 1.51% resist-
ance in Germany (6 ⁄ 398 isolates), 0.4% resistance
in Slovakia (10 ⁄ 250 isolates), and 0.56% resistance
in Poland (3 ⁄ 535 isolates) (http://www.esbic.de/
esbic/esar/results2001/esar-body116htm).
Aminoglycosides
Aminoglycosides are used widely for the treat-
ment of Acinetobacter infections, but increasing
numbers of highly resistant strains have been
reported since the late 1970s.
The most frequent cause of resistance to ami-
noglycosides in Acinetobacter spp. is the modifi-
cation of hydroxyl or amino groups of the
antibiotic by aminoglycoside-modifying enzymes.
All three types of aminoglycoside-modifying
enzymes (acetylases, adenylases and phospho-
transferases) have been detected in clinical iso-
lates of Acinetobacter spp. [40,95]. However,
geographical variations have been observed. For
example, the gene for AAC(3)-Ia was found
frequently in isolates of Acinetobacter spp. from
Belgium (36 of 45 strains) [96], but in only two of
54 strains from Spain [34]. Various adenylating
enzymes have been described in Acinetobacter spp.
In Spain, 15% of the 54 clinical A. baumannii
isolates studied contained ANT(3¢¢)9, which
modifies streptomycin and spectinomycin [34].
The phosphotransferase found most frequently in
Acinetobacter spp. is APH(3¢)VI. In 1990, Lambert
et al. [97] described the dissemination of the aph6
gene in France, and APH(3¢)VI was detected in 15
of the 54 clinical A. baumannii isolates studied in
Spain [34]. In addition, it was demonstrated that
the spread of amikacin resistance in A. baumannii
isolated in Spain was associated with an epidemic
strain carrying the aph(3¢)-VIa gene [29]. A. hae-
molyticus and related species are intrinsically
resistant to aminoglycosides through synthesis
of the chromosomally encoded specific N-acetyl-
transferase AAC(6¢) [98, 99]. Other mechanisms of
resistance to aminoglycosides in Acinetobacter spp.
include alterations of the target ribosomal protein,
and ineffective transportation of the antibiotic to
the interior of bacteria [34]. In 2001, Magnet et al.
[100] described a resistance-nodulation-cell divi-
sion-type efflux pump involved in aminoglyco-
side resistance in a multiresistant A. baumannii
isolate from a patient with urinary tract infection.
This efflux pump was also shown to affect the
level of susceptibility to other drugs, including
fluoroquinolones, tetracyclines, chloramphenicol
and trimethoprim.
Resistance to aminoglycosides is relatively
common in clinical isolates of Acinetobacter spp.
In a study performed in Germany in 1990, only
57% of 23 isolates from ICU patients were
susceptible to gentamicin, and 78% were suscept-
ible to tobramycin [65]. In The Netherlands,
11 Acinetobacter spp. isolated in 1990 from patients
of eight hospitals were all susceptible to amikacin,
with 72% susceptible to tobramycin, and 45% to
gentamicin [66]. In 1994–1995, the percentages of
gentamicin-susceptible Acinetobacter spp. isolates
from ICU patients were 82% in Belgium, 34% in
France, 36% in Portugal, 19% in Spain and 100%
in Sweden. For amikacin, the figures were 85% in
Belgium, 64% in France, 90% in Portugal and
49% in Spain [67,68].
Of 70 Acinetobacter spp. isolated in 1990 from
Belgian ICU patients, 57% were susceptible to
amikacin, 49% to tobramycin and 43% to gen-
tamicin [69]. Between 1996 and 1999, 83% of 41
Acinetobacter spp. isolates from ICUs of Belgian
hospitals in 1996–1997 were susceptible to gen-
tamicin, compared with 56% of 11 isolates in
1998–1999 [71]. A French study in 1991 found that
19% and 28%, respectively, of 268 A. baumannii
isolates from ICU patients were susceptible to
gentamicin and tobramycin [75].
In a Spanish study during the early 1990s, 50%
of 54 A. baumannii isolates tested were susceptible
to tobramycin, 33% to gentamicin, 66% to neti-
lmicin, and 72% to amikacin and isepamicin [34].
Of 177 A. calcoaceticus–A. baumanni complex iso-
lates from patients admitted to a Spanish teaching
hospital between 1990 and 1994, 94% were sus-
ceptible to amikacin [76]. Between 1991 and 1996,
an increase in aminoglycoside resistance among
clinical isolates of Acinetobacter spp. was noticed in
Spain, rising from 33.0% to 71.8% for tobramycin,
and from 21.0% to 83.7% for amikacin [77].
The Greek System for Surveillance of Antimi-
crobial Resistance reported in 1996 that 41.5%
and 75.6%, respectively, of A. baumannii ICU
isolates were resistant to netilmicin and gentam-
icin, while resistance rates of 51.6% and 58.4%,
respectively, were reported in hospital wards
(http://mednet.gr/whonet) [82]. In 1998, 121
A. baumannii isolates from ICU patients of nine
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hospitals in Greece showed resistance levels of
87.6% and 56.2%, respectively, to gentamicin and
netilmicin, while amikacin retained activity
against 70.2% of the isolates [83].
In Turkey, only 8.7% of 80 isolates from ICUs
in 1996 were susceptible to gentamicin and only
29.1% to amikacin [84]. In 1997, of 164 isolates of
Acinetobacter spp., 17.1% were susceptible to
gentamicin and 34.8% to amikacin [85]. Of 32
A. baumannii isolates from Turkish ICUs in 1999,
62.5% were susceptible to amikacin and 15.6% to
gentamicin [87]. In Croatia in 1999, 25% of
isolates were resistant to amikacin and 26% to
netilmicin [88], while in a Slovakian study of 2002,
58% of 50 Acinetobacter spp. isolates (A. baumannii,
A. lwoffii, A. calcoaceticus, A. haemolyticus) were
resistant to gentamicin, 44% to amikacin and 24%
to netilmicin [89]. In Estonia, 27% of isolates of
Acinetobacter spp. from ICUs were susceptible to
gentamicin in 1995, decreasing to 19% in 1998,
while susceptibility to amikacin decreased from
95% in 1995 to 60% in 1998 [91]. In Russia, 91% of
77 Acinetobacter spp. isolates in 1995–1996 were
resistant to gentamicin, while only 7% were
resistant to amikacin [92].
In the 1997–1998 European SENTRY study,
tobramycin showed the greatest activity of the
tested aminoglycosides against Acinetobacter spp.,
with 60.2% of 279 strains susceptible. Suscep-
tibilities to amikacin and gentamicin were 58.1%
and 43.4%, respectively [101]. Of 247 Acinetobacter
spp. isolates from blood cultures, 62.4% were
susceptible to tobramycin, 59.1% to amikacin and
48.6% to gentamicin [93]. During a 3-month
period in 1997, 41 Acinetobacter spp. isolates
associated with skin and soft tissue infections
were isolated in 20 European hospitals. Suscepti-
bilities to amikacin, gentamicin and tobramycin
were 46.3%, 34.2% and 43.9%, respectively [94].
Quinolones
Until 1988, quinolones had good activity against
Acinetobacter strains [102] compared to expanded-
spectrum cephalosporins and aminoglycosides.
However, resistance to these antibiotics has
emerged rapidly in clinical isolates [32–34].
Resistance of A. baumannii to the fluoroquinolones
has been attributed to changes in the structure of
DNA gyrase or topoisomerase IV, caused by
mutations in the gyrA or parC genes, respectively,
which lower the affinity of the drug for the
enzyme–DNA complex [103–106]. A second
mechanism of resistance involves mutations
of chromosomally-encoded drug-influx and
-efflux systems that determine intracellular drug
accumulation [103,105,107]. These mutations
result either in reduced production of specific
outer-membrane proteins which mediate quino-
lone influx, or over-expression of some efflux
system(s), leading to active drug expulsion. Two
studies suggesting the involvement of efflux
pumps in the acquisition of resistance to quino-
lones in A. baumannii have been published
[108,109].
In Germany, 96% of Acinetobacter spp. isolates
from ICU patients were susceptible to ciprofloxa-
cin [65], and all 11 Acinetobacter spp. isolated in
1990 from patients of eight Dutch hospitals were
susceptible to ciprofloxacin [66]. In 1994–1995,
susceptibilities to ciprofloxacin in isolates from
ICU patients were 82% in Belgium, 22% in
France, 25% in Portugal, 19% in Spain and 81%
in Sweden [67, 68]. In Belgium, 51% of the 70
Acinetobacter spp. isolates from ICU patients in
1990 were susceptible to ciprofloxacin [69], while
76% of the 41 Acinetobacter spp. isolated in 1997
from Belgian ICUs were susceptible to ciprofloxa-
cin, compared with 56% of the 11 isolates in 1999
[71]. Of the 268 A. baumannii isolated from the
ICUs of 39 French teaching hospitals in 1991, 18%
were susceptible to ciprofloxacin [75].
In Spain, Vila et al. [34] found ciprofloxacin
(70%) and ofloxacin (72%) to be more active
against clinical isolates of A. baumannii than
norfloxacin (18%), but in a separate study,
ciprofloxacin resistance in clinical isolates of
Acinetobacter increased in Spain from 54.4% in
1991 to 90.4% in 1996 [77].
In 1996 in Greece, 76.6% of the A. baumannii
isolates from wards, and 92.4% of the ICU
isolates, were resistant to ciprofloxacin (http://
mednet.gr/whonet) [82]. Of 121 A. baumannii
isolates collected in 1998 from Greek ICUs,
92.6% were resistant to ciprofloxacin [83]. In
1996 in Turkey, 26.4% of Acinetobacter spp. iso-
lates from ICUs were susceptible to ciprofloxacin
[84] compared with 32.9% in 1997 [85], while a
separate study in 1999 found that 31.3% of 32
A. baumannii isolates from ICUs were susceptible
to ciprofloxacin [87].
In a Slovakian study published in 2002, 68%
of the 50 tested Acinetobacter spp. isolates (A. bau-
mannii, A. lwoffii, A. calcoaceticus, A. haemolyticus)
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were resistant to ciprofloxacin [89], while 81.3%
of 32 Acinetobacter spp. isolates collected from
children in a Polish ICU between 1997 and 2000
were susceptible to ciprofloxacin [90]. In 1995,
67% of Acinetobacter spp. isolates from Estonian
ICUs were susceptible to ciprofloxacin, decreas-
ing to 33% in 1998 [91]. Of 77 Acinetobacter spp.
strains isolated in Russia from patients with ICU-
acquired infections, 53% were resistant to ciprofl-
oxacin [92].
Of the 279 clinical Acinetobacter spp. isolates
from 20 European university hospitals participa-
ting in the 1997–1998 SENTRY study, 45.2%,
46.6% and 47.3% were susceptible to ciprofloxa-
cin, ofloxacin and levofloxacin, respectively.
Gatifloxacin and trovafloxacin showed the best
in-vitro activities against Acinetobacter spp. [110].
Quinolones showed poor activity against Acine-
tobacter spp. from blood cultures. Only 50.6%,
52.6% and 54.7% of the 247 isolates showed in-
vitro susceptibility to ciprofloxacin, ofloxacin and
levofloxacin, respectively. Similar resistance rates
were seen throughout the different European
centres [93]. Of the 41 Acinetobacter spp. isolates
associated with skin and soft tissue infections,
41.5%, 46.3% and 48.8% were susceptible to
ciprofloxacin, ofloxacin and levofloxacin, respect-
ively [94].
Between 1997 and 1999, 368 A. baumannii
isolates were collected from 16 European coun-
tries. Susceptibilities to gemifloxacin, ciprofloxa-
cin, levofloxacin and ofloxacin were 53.8%,
49.7%, 61.7% and 51.4%, respectively. The iso-
lates of A. anitratus, A. calcoaceticus, A. haemolyticus
and A. lwoffii investigated were less resistant than
those of A. baumannii [111].
Other antibiotics
A. baumannii has a high degree of resistance to
both chloramphenicol and trimethoprim–sulpha-
methoxazole, but little is known about the genetic
basis of resistance to these compounds in these
bacteria. Devaud et al. [40] found that chloram-
phenicol resistance involves the synthesis of
chloramphenicol acetyltransferase I (CAT1). The
CAT1 gene has been associated with both chro-
mosomal and plasmid DNA in a clinical
Acinetobacter isolate, suggesting that the CAT1
gene might be transposon-encoded, thereby
improving its survival potential by being located
in both replicons [112]. However, in another
study, CAT1 activity was not detected, suggesting
that resistance could result from a change in
permeability to the antibiotic or a mutation in the
target protein [34]. Similarly, Goldstein et al. [39]
studied a multiresistant strain of A. calcoaceticus
var. anitratus and found that resistance to chlo-
ramphenicol was not associated with CAT pro-
duction. In a Spanish study published in 1993, all
54 A. baumanni isolates tested were resistant to
chloramphenicol [34]. In other bacteria, resistance
to sulphonamides is normally caused by the
acquisition of plasmids encoding resistant ver-
sions of the target protein, dihydropteroate syn-
thase. Similarly, high-level trimethoprim
resistance is generally caused by the acquisition
of plasmid DNA carrying a dhfr gene encoding a
dihydrofolate reductase with low affinity for
trimethoprim [113]. No specific studies on mech-
anisms of resistance to these antibiotics in Acine-
tobacter spp. have been published.
A Spanish study on the evolution of resistance
among clinical isolates of Acinetobacter found that
41.1% and 88.9% of isolates were resistant to
trimethoprim-sulphamethoxazole in 1991 and
1996, respectively [77]. Of 109 isolates in Spain
between 1997 and 1999 from patients with no-
socomial A. baumannii bacteraemia, 85% were
resistant to trimethoprim-sulphamethoxazole
[79]. In a Spanish study published in 1993, 63%
of 54 A. baumannii isolates tested were susceptible
to trimethoprim–sulphamethoxazole [34]. In 1999,
43.8% of 32 A. baumannii isolates from the ICUs of
four different hospitals in Turkey were suscept-
ible to trimethoprim–sulphamethoxazole [87],
while in a Slovakian study published in 2002,
58% of 50 Acinetobacter spp. isolates (A. baumannii,
A. lwoffii, A. calcoaceticus, A. haemolyticus) were
resistant to trimethoprim–sulphamethoxazole [89].
Of the 77 Acinetobacter spp. isolates from patients
with ICU-acquired infections in ten Russian
hospitals, 88% were resistant to trimethoprim–
sulphamethoxazole [92].
Tetracycline acts by binding to the 30S ribo-
somal subunit, resulting in the inhibition of
protein synthesis [114]. Tetracycline-resistant bac-
teria generally express one of two different
resistance mechanisms: an efflux pump or a
ribosomal protection system. Different tetracyc-
line resistance determinant classes have been
recognised and classified, with classes A–E being
detected most frequently among Gram-negative
bacteria. As most tetracycline resistance genes
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have been found on plasmids or transposons,
acquisition of resistance is generally assumed to
be mediated mainly by gene transfer [115].
Guardabassi et al. [116] found the TetA and TetB
determinants in clinical and aquatic strains of
A. baumannii. A transposon containing the tetA
determinant was characterised partially by Ribera
et al. [117], who also detected the presence of
the TetM determinant in a clinical isolate of
A. baumannii [118].
Different publications have reported excellent
activity of doxycycline or minocycline, but not
tetracycline, against Acinetobacter spp. [34,119].
This may result from the fact that TetA, the
major tetracycline resistance determinant, con-
fers resistance to tetracycline, but not to mino-
cycline. In a Spanish study of the early 1990s,
98% of 54 A. baumannii isolates tested were sus-
ceptible to doxycycline [34]. Of 109 A. baumannii
isolates tested in Spain between 1997 and 1999,
85% were resistant to tetracycline [79]. Tigecy-
cline, a new glycylcycline, was evaluated in the
UK with 595 Acinetobacter spp. isolated during
2000 from routine clinical specimens at 54
sentinel laboratories. Tigecycline was found to
be less active than minocycline, but both agents
overcame most tetracycline resistance [72]. In the
1997–1998 SENTRY study, 247 Acinetobacter spp.
were isolated from blood cultures, of which 51%
were susceptible to tetracycline [93]. Of 41
Acinetobacter spp. isolates in 1997 that were
associated with skin and soft tissue infections,
43.9% were susceptible to tetracycline [94].
GENETICS OF RESISTANCE
Acinetobacter is a genus that appears to have a
propensity to develop antibiotic resistance extre-
mely rapidly, perhaps as a consequence of its
long-term evolutionary exposure to antibiotic-
producing organisms in soil [12]. Furthermore,
Acinetobacter spp., and A. baumannii in particular,
are intrinsically resistant to many of the antimi-
crobial agents used most commonly [120].
A major contributing factor in the emergence of
resistant Acinetobacter spp. is the acquisition and
transfer of antibiotic resistance on plasmids,
transposons and integrons. Several studies have
reported that > 80% of Acinetobacter spp. isolates
carry multiple indigenous plasmids of various
molecular sizes [121,122], although another report
found plasmids in only 28% of the clinical isolates
of A. baumannii analysed [123]. In a recent Dutch
study, plasmids were detected in 42% (20 ⁄ 48) of
Acinetobacter isolates [124].
Transposons probably play an important role,
in conjunction with integrons [125], in ensuring
that particular novel genes can become estab-
lished in a new gene pool. Different studies have
reported chromosomally-located transposons car-
rying multiple antibiotic resistance genes in clin-
ical isolates of Acinetobacter spp. [126].
The presence of integrons in Acinetobacter spp.
has been well-described, as has their relatively
high frequency of carriage in epidemic strains
[124,127]. Three main classes of integrons have
been described. Class 1 integrons (mostly associ-
ated with the sul1 gene) include the gene encoding
the Int1 integrase (intI1). Class 2 integrons (related
to transposon Tn7 and its close relatives) have a
defective intI gene (intI2*) with partial homology
to intI1. Class 3 integrons encode the IntI3 integ-
rase, showing 60.9% homology with the amino-
acid sequence of the IntI1 integrase [128]. Most
investigators have found predominantly class 1
integrons in Acinetobacter spp. [124,129,130].
However, Gonzalez et al. [131] found predomin-
antly class 2 integrons in A. baumannii isolates
from Chilean hospitals. Possibly, the isolates from
the latter study were more genetically related.
Among A. baumannii integrons, a high prevalence
of genes encoding aminoglycoside-modifying
enzymes and b-lactamases have been found
[41,129,130,132]. Seward and Towner [129] found
similar integrons in genotypically distinct Acine-
tobacter spp. isolates from different locations
worldwide. This is in agreement with the findings
of Gombac et al. [127], who found that integron
structures with the same variable region can be
retrieved from genotypically distinguishable
strains, and with the findings of Ribera et al. [133],
who demonstrated that non-related A. baumannii
isolates from different geographical areas are able
to acquire common integrons.
Characterisation of integron structure in epi-
demiologically unrelated strains of A. baumannii
suggests, based on integron structure similarity,
that inter-species transfer may have occurred
from Enterobacteriaceae [127]. Similarly, in a
Spanish study, the integrons carried genes that
were identical or closely related to genes found
previously in integrons from organisms such as
Pseudomonas aeruginosa, suggesting the potential
transfer of genetic material between A. baumannii
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and P. aeruginosa [134]. On the other hand, related
strains possessing unrelated integrons have also
been found [134].
TREATMENT OPTIONS FOR
CARBAPENEM-RESISTANT
ACINETOBACTER SPP .
Very few of the major antibiotics are now reliably
effective for the treatment of severe nosocomial
Acinetobacter infections, particularly in patients
confined to ICUs. Until recently, the recommen-
ded drugs for therapy were extended-spectrum
penicillins, broad-spectrum cephalosporins or
carbapenems, combined with an aminoglycoside
[12]. However, increasing resistance to these
antimicrobial agents necessitates a critical apprai-
sal of the remaining antibiotic treatment options.
Sulbactam is a synthetic b-lactam molecule,
with structural, chemical and pharmacokinetic
properties similar to those of the aminopenicillins.
A feature that distinguishes sulbactam from other
available b-lactamase inhibitors is its direct anti-
microbial activity against Bacteroides fragilis and
Acinetobacter spp., organisms against which most
cephalosporins display little or no activity [135].
Binding of sulbactam to PBP2 of these organisms
results in intrinsic antibacterial activity [136].
Most studies have investigated only the ampi-
cillin–sulbactam combination, since sulbactam
alone is not available commercially in many
countries. In 1993, ampicillin–sulbactam was used
for the treatment of ten patients with infections
caused by imipenem-resistant A. calcoaceticus, nine
of whom improved clinically [137]. In 1996, a
prospective observational study followed 79
patients with A. baumannii bacteraemia. Ampicil-
lin–sulbactam was used in eight patients, with a
cure rate of 88% [138]. In 1997, a series of patients
with multiresistant A. baumannii meningitis who
were treated with ampicillin–sulbactam was
reported. Eight cases of nosocomial meningitis
were treated with ampicillin–sulbactam 2 g + 1 g
every 6 h (seven patients) or 2 g + 1 g every 8 h
(one patient). All isolates were resistant to gen-
tamicin, ceftazidime and ciprofloxacin, while
seven of eight were imipenem-resistant. Six
patients were cured, while two died of meningitis
[139]. Corbella et al. [140] treated 42 patients with
non-life-threatening multiresistant A. baumannii
infections, including seven bacteraemias, with
sulbactam alone and in combination with ampi-
cillin (1 g every 8 h); 39 improved or were cured
with no major adverse effects. In this study, killing
curves showed that sulbactam was bacteriostatic,
and no synergy was observed between ampicillin
and sulbactam. The authors suggested a role for
sulbactam in non-life-threatening infections
caused by A. baumannii. A retrospective analysis
(1987–1999) compared treatment outcomes of 48
patients with A. baumannii bacteraemia treated
with imipenem–cilastatin or ampicillin–sulbactam
for ‡ 72 h. Ampicillin–sulbactam was at least as
effective as imipenem–cilastatin and was a cost-
effective alternative for treatment [141].
Unfortunately, emergence of resistance to sul-
bactam has been noted in imipenem-resistant
strains of A. baumannii, leaving the polymyxins
(colistimethate and polymyxin B) as the only
treatment alternative [142]. Colistin is rapidly
bactericidal and exerts its effects by acting as a
cationic detergent, causing disruption of the
integrity of the bacterial cell membrane, with
leakage of intracellular contents and cell death
[143]. Resistance to colistin has been postulated
to occur via decreased affinity of lipopolysac-
charides for colistin [143]. Colistin was used in
the 1960s and 1970s, but was abandoned because
of adverse side effects, including nephrotoxicity,
neuromuscular blockade and neurotoxicity [144],
and because of the emergence of newer and safer
antimicrobials. Levin et al. [144] reported the
outcomes following treatment with colistin of 60
nosocomial infections caused by multiresistant
A. baumannii and P. aeruginosa. There was a good
outcome for 35 (58%) patients, while three
patients died within the first 48 h of treatment.
The poorest results were observed in cases of
pneumonia, where only five (25%) of 20 patients
had a good outcome. The main adverse effect of
treatment was renal failure (27% in patients with
initial normal renal function, and 58% in
patients with initial abnormal renal function);
nevertheless, colistin can be recommended for
the treatment of severe infections caused by
multiresistant A. baumannii. In 2002, Jimenez-
Mejias et al. [145] reported a case of meningitis
caused by multiresistant A. baumannii which was
treated successfully with intravenous colistin
sulphomethate sodium (5 mg ⁄ kg ⁄day). Colistin
penetrated the cerebrospinal fluid at one-quarter
the serum levels without adverse effects. In 1994,
Go et al. [146] reported a nosocomial outbreak
of infections caused by imipenem-resistant
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A. baumannii in a New York hospital. Infection
and colonisation were eliminated by intensive
infection control measures, and wound irrigation
with polymyxin B.
CONCLUSIONS
Acinetobacter spp. are important nosocomial path-
ogens, capable of rapid adaptation to the hospital
environment. There is no doubt that these organ-
isms will pose continuing problems, which is
disturbing because of the extent of their antibi-
otic resistance profiles. Although antimicrobial
resistance of Acinetobacter spp. appears to be
increasing across Europe, it is difficult to esti-
mate accurately the extent of this emerging
problem, in part because the published suscep-
tibility data are based on different methods, and
also because of population bias and clonal
variation. A reference method for susceptibility
testing and MIC breakpoints should be estab-
lished to better monitor trends of resistance.
Surveillance of antimicrobial resistance, the
study of resistance mechanisms, the develop-
ment of new drugs, and the prevention of the
spread of multiresistant strains, are all important
measures required to control the impact of these
multiresistant bacteria.
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